Trial Profile

Real-world experience from the TRIO network assessing outcomes in patients with chronic hepatitis C treated with elbasvir/grazoprevir in the United States

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Jun 2018 Updated results (n=319) of retrospective data analyses assessing utilization and outcomes with elbasvir/grazoprevir (EBR/GZR)-containing regimens in an updated cohort of genotype 1B chronic hepatitis C patients treated as part of the TRIO network in the US, presented at the Digestive Disease Week 2018.
05 Jun 2018 Updated results (n=115) presented at the Digestive Disease Week 2018.
17 Apr 2018 Results (n=470) assessing uptake, healthcare utilization and outcomes of chronic hepatitis C treated with elbasvir/grazoprevirin the United States, were published in the Alimentary Pharmacology and Therapeutics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com